Nurix Therapeutics, Inc. (NRIX)

NASDAQ: NRIX · Real-Time Price · USD

15.81

-0.16 (-1.00%)

At close: Mar 2, 2026, 4:00 PM EST

15.40

-0.41 (-2.59%)

Pre-market: Mar 3, 2026, 8:19 AM EST

Nurix Therapeutics Income Statement

Financials in millions USD. Fiscal year is December - November.

Millions USD. Fiscal year is Dec - Nov.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov '25 Nov 30, 2025	Nov '24 Nov 30, 2024	Nov '23 Nov 30, 2023	Nov '22 Nov 30, 2022	Nov '21 Nov 30, 2021
Revenue	83.98	54.55	76.99	38.63	29.75
Revenue Growth (YoY)	53.95%	-29.14%	99.31%	29.84%	66.95%
Cost of Revenue	316.9	221.63	189.15	184.5	116.43
Gross Profit	-232.92	-167.08	-112.16	-145.87	-86.68
Selling, General & Admin	52.74	45.94	42.9	38	31.2
Operating Expenses	52.74	45.94	42.9	38	31.2
Operating Income	-285.67	-213.03	-155.06	-183.87	-117.89
Interest & Investment Income	21.97	19.73	11.12	3.51	0.82
Pretax Income	-263.7	-193.3	-143.95	-180.36	-117.06
Income Tax Expense	0.76	0.27	-	-	0.13
Net Income	-264.46	-193.57	-143.95	-180.36	-117.19
Net Income to Common	-264.46	-193.57	-143.95	-180.36	-117.19
Shares Outstanding (Basic)	87	67	54	49	43
Shares Outstanding (Diluted)	87	67	54	49	43
Shares Change (YoY)	29.12%	23.52%	11.79%	13.32%	173.68%
EPS (Basic)	-3.05	-2.88	-2.65	-3.71	-2.73
EPS (Diluted)	-3.05	-2.88	-2.65	-3.71	-2.73
Free Cash Flow	-263.47	-181.86	-89.77	-172.05	-90.03
Free Cash Flow Per Share	-3.04	-2.71	-1.65	-3.54	-2.10
Gross Margin	-277.36%	-	-145.69%	-	-291.38%
Operating Margin	-340.16%	-390.52%	-201.41%	-476.01%	-396.25%
Profit Margin	-314.90%	-354.85%	-186.98%	-466.93%	-393.93%
Free Cash Flow Margin	-313.73%	-333.38%	-116.60%	-445.42%	-302.61%
EBITDA	-277.53	-205.01	-148.93	-179.72	-115.9
EBITDA Margin	-	-	-193.45%	-	-
D&A For EBITDA	8.14	8.02	6.13	4.15	1.99
EBIT	-285.67	-213.03	-155.06	-183.87	-117.89
EBIT Margin	-	-	-201.41%	-	-
Revenue as Reported	83.98	54.55	76.99	38.63	-

Updated Nov 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q